{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:47:56Z","timestamp":1771307276336,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jtct.2024.09.024","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T13:59:38Z","timestamp":1728655178000},"page":"1178-1188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable\/Progressive Large B Cell Lymphoma at Lymphodepletion\u2014A Phase 2, Prospective Interventional Study"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8683-6930","authenticated-orcid":false,"given":"Ron","family":"Ram","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-5047","authenticated-orcid":false,"given":"Odelia","family":"Amit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chava","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yair","family":"Herishanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadav","family":"Sarid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arie","family":"Apel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meir","family":"Preis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Aviv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirly","family":"Shapira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamir","family":"Shragai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erel","family":"Joffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6429-148X","authenticated-orcid":false,"given":"Liat","family":"Shargian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Herzog-Tsarfati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nili","family":"Eylati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Acria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-8793","authenticated-orcid":false,"given":"Gil","family":"Fridberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronit","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Glait-Santar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigi","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinneret","family":"Gal-Rabinovich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1407-9210","authenticated-orcid":false,"given":"Noga","family":"Setter-Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofrat","family":"Beyar-Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.09.024_bib0001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.09.024_bib0002","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.09.024_bib0003","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.09.024_bib0004","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.09.024_bib0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.09.024_bib0006","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2024.09.024_bib0007","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.09.024_bib0008","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.09.024_bib0009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-024-01022-w","article-title":"Reducing and controlling metabolic active tumor volume prior to CAR T-cell infusion can improve survival outcomes in patients with large B-cell lymphoma","volume":"14","author":"Keijzer","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2024.09.024_bib0010","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.09.024_bib0011","first-page":"11","article-title":"Day+7 anti CD19-CAR-T blood concentrations identify ultra-high-risk group for early progression of disease in patients with stable\/progress IVE DLBCL at lymphodepletion","volume":"57","author":"Ram","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.09.024_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1152498","article-title":"Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell malignancies","volume":"14","author":"Garc\u00eda-Calder\u00f3n","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2024.09.024_bib0013","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2024.09.024_bib0014","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.3390\/cells11071140","article-title":"Molecular and functional signatures associated with CAR T cell exhaustion and impaired clinical response in patients with B cell malignancies","volume":"11","author":"Beider","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jtct.2024.09.024_bib0015","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","article-title":"In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtct.2024.09.024_bib0016","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxs098","article-title":"PD-1 is a novel regulator of human B-cell activation","volume":"25","author":"Thibult","year":"2013","journal-title":"Int Immunol"},{"key":"10.1016\/j.jtct.2024.09.024_bib0017","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.3390\/cancers12113285","article-title":"The immune checkpoint PD-1 in natural killer cells: expression, function and targeting in tumour immunotherapy","volume":"12","author":"Quatrini","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2024.09.024_bib0018","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1189\/jlb.0813443","article-title":"Negative role of inducible PD-1 on survival of activated dendritic cells","volume":"95","author":"Park","year":"2014","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jtct.2024.09.024_bib0019","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.09.024_bib0020","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"9","author":"Cao","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2024.09.024_bib0021","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1182\/blood-2019-129120","article-title":"Portia: a phase 1b study evaluating safety and efficacy of tisagenlecleucel and pembrolizumab in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"134","author":"Jaeger","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.09.024_bib0022","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.09.024_bib0023","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.09.024_bib0024","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/bloodadvances.2022007779","article-title":"Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r\/r DLBCL: phase 1b PORTIA study results","volume":"7","author":"Jaeger","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.09.024_bib0025","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-CT055","article-title":"Abstract CT055: phase 1\/2 primary analysis of ZUMA-6: axicabtagene ciloleucel (Axi-Cel) in combination with atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)","volume":"80","author":"Jacobson","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtct.2024.09.024_bib0026","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2024.09.024_bib0027","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2024.09.024_bib0028","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00262-020-02681-x","article-title":"Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1","volume":"70","author":"Makowska","year":"2021","journal-title":"Cancer Immunol Immunother"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724006924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724006924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T03:48:41Z","timestamp":1764560921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724006924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2666636724006924"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.09.024","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable\/Progressive Large B Cell Lymphoma at Lymphodepletion\u2014A Phase 2, Prospective Interventional Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}